Search results for "trials"

showing 10 items of 966 documents

Statins, Fracture Risk, and Bone Remodeling: What Is True?

2006

Besides the action on plasma lipid levels, statins show a series of ancillary effects defined as all of their vascular and nonvascular effects independent from the cholesterol reduction. It has been recently hypothesized that one of these ancillary effects could be the improvement of bone health, due to the interference with bone metabolism. This may potentially represent the rationale for statins' use in the treatment of osteoporosis, the most common disease of the bone. Both experimental observations and clinical studies on this topic generated a number of conflicting results; however, the largest randomized clinical trials, the Scandinavian Simvastatin Survival Study (4S), Long Term Inte…

MaleRiskSimvastatinmedicine.medical_specialtyOsteoporosisMyocardial IschemiaBioinformaticsBone remodelinglaw.inventionFractures Bonechemistry.chemical_compoundRandomized controlled trialRisk FactorslawHumansMedicineLongitudinal StudiesRisk factorPravastatinRandomized Controlled Trials as Topicbusiness.industryCholesterolOsteoporosiStatinnutritional and metabolic diseasesGeneral Medicinemedicine.diseaseSurgerychemistrySimvastatinOsteoporosisFemalelipids (amino acids peptides and proteins)Bone RemodelingTherapyHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessFracturesHeart Protection StudyPravastatinmedicine.drugThe American Journal of the Medical Sciences
researchProduct

A long-term (two years) clinical trial with S-adenosylmethionine for the treatment of osteoarthritis

1987

In a long-term multicenter open trial involving 10 general practitioners, the efficacy and tolerance of S-adenosylmethionine (SAMe) were studied for 24 months in 108 patients with osteoarthritis of the knee, hip, and spine. At the end of the 24-month observation period, 97 of the patients were still in the study. The patients received 600 mg of SAMe daily (equivalent to three tablets of 200 mg each) for the first two weeks and thereafter 400 mg daily (equivalent to two tablets of 200 mg each) until the end of the 24th month of treatment. Separate evaluations were made for osteoarthritis of the knee, hip, cervical spine, and dorsal/lumbar spine. The severity of the clinical symptoms (morning…

MaleS-Adenosylmethioninemedicine.medical_specialtyClinical effectivenessOsteoarthritisOsteoarthritisHumansMedicineLongitudinal StudiesAdverse effectAgedClinical Trials as TopicPsychological TestsDepressionbusiness.industryAnti-Inflammatory Agents Non-SteroidalMorning stiffnessGeneral MedicineMiddle Agedmedicine.diseaseCervical spineSurgeryClinical trialFemaleLumbar spineOpen labelbusinessThe American Journal of Medicine
researchProduct

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

2017

Item does not contain fulltext BACKGROUND: Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk. METHODS: In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned the 27,438 patients in the combined trials to receive bococizumab (at a dose of 150 mg) subcutaneously every 2 weeks or placebo. The primary end point was nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina requiring urgent re…

MaleSTATIN THERAPYAnticholesteremic Agents/adverse effectsAntibodieVascular damage Radboud Institute for Health Sciences [Radboudumc 16]Injections Subcutaneous/adverse effects030204 cardiovascular system & hematologyBococizumablaw.inventionPCSK90302 clinical medicineRandomized controlled triallawRisk FactorsGENETIC-VARIANTSCardiovascular DiseaseMonoclonalAnticholesteremic Agent030212 general & internal medicineMyocardial infarctionTreatment FailureHumanizedProprotein Convertase 9/antagonists & inhibitorsMedicine(all)Antibodies; Antibodies Monoclonal Humanized; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol LDL; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Injections Subcutaneous; Lipids; Male; Middle Aged; Proprotein Convertase 9; Risk Factors; Treatment Failure; Medicine (all)Anticholesteremic AgentsMedicine (all)PCSK9 InhibitorsAntibodies; antibodies monoclonal humanized; anticholesteremic agents; cardiovascular diseases; cholesterol LDL; double-blind method; female; follow-up studies; humans; hypercholesterolemia; injections subcutaneous; lipids; male; middle aged; proprotein convertase 9; risk factors; treatment failure; medicine (all)Vascular damage Radboud Institute for Molecular Life Sciences [Radboudumc 16]General MedicineLipidMiddle AgedLipids3. Good healthLDL/bloodMulticenter StudyCholesterolTRIALSCholesterol LDL/bloodCardiovascular DiseasesAntibodies Monoclonal Humanized/adverse effectsanticholesteremic agentsRandomized Controlled Trialsubcutaneouslipids (amino acids peptides and proteins)FemaleProprotein Convertase 9Cardiovascular Diseases/prevention & controlREDUCING LIPIDSHumanmedicine.medical_specialtyanimal structuresInjections SubcutaneousHypercholesterolemiaHypercholesterolemia/drug therapyPlaceboAntibodies Monoclonal HumanizedInjections SubcutaneouAntibodiesLDLInjectionsFollow-Up StudielipidsEVENTS03 medical and health sciencesantibodies monoclonal humanizedDouble-Blind MethodInternal medicinemedicineJournal ArticleHumansComparative StudyMETAANALYSISAlirocumabbusiness.industryUnstable anginaLipids/bloodPCSK9Risk FactorfungiAntibodies/bloodCholesterol LDLta3121medicine.diseaseSurgerycardiovascular diseasesEvolocumabREDUCTIONHumanized/adverse effectsSubcutaneous/adverse effectsbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up Studies
researchProduct

The role of pain and functional impairment in the decision to recommend total joint replacement in hip and knee osteoarthritis: an international cros…

2011

Import JabRef | WosArea Orthopedics; Rheumatology; International audience; Objective: To assess the pain and functional disability levels corresponding to an indication for total joint replacement (TJR) in hip and knee osteoarthritis (OA). Methods: Design: International cross-sectional study in 10 countries. Patients: Consecutive outpatients with definite hip or knee OA attending an orthopaedic outpatient clinic. Gold standard measure for recommendation for TJR: Surgeon's decision that TJR is justified. Outcome measures: Pain (ICOAP: intermittent and constant osteoarthritis pain, 0-100) and functional impairment (HOOS-PS/KOOS-PS: Hip/Knee injury and Osteoarthritis Outcome Score Physical fun…

MaleSURGERYmedicine.medical_treatmentArthroplasty Replacement HipOsteoarthritisSeverity of Illness IndexOsteoarthritis HipRADIOGRAPHIC FEATURESDisability Evaluation0302 clinical medicineMedicineOutpatient clinicOrthopedics and Sports Medicine030212 general & internal medicinePREDICTORSArthroplasty Replacement KneePain Measurement/methodsPain/diagnosisPain Measurementddc:616ASSOCIATIONOsteoarthritis KneeMiddle Aged3. Good healthPRIORITIZATIONTRIALS[ SCCO.NEUR ] Cognitive science/NeuroscienceFemaleOsteoarthritis Hip/physiopathology/surgerymusculoskeletal diseasesmedicine.medical_specialtyJoint replacementSymptomDecision MakingBiomedical EngineeringPainArticle03 medical and health sciencesRheumatologySeverity of illnessOsteoarthritisPHYSICAL-FUNCTIONHumansKneeARTHROPLASTYRheumatology and AutoimmunityAged030203 arthritis & rheumatologyHip surgeryHipOsteoarthritis Knee/physiopathology/surgerybusiness.industry[SCCO.NEUR]Cognitive science/NeuroscienceJoint replacementGold standard[SCCO.NEUR] Cognitive science/NeuroscienceOUTCOME MEASUREKnee Hip Osteoarthritis Joint replacement Surgery Symptom radiographic features physical-function outcome measure arthroplasty severity surgery trials prioritization association predictorsmedicine.diseaseArthroplastySEVERITYCross-Sectional StudiesOrthopedic surgeryPhysical therapySurgerybusiness
researchProduct

Effects of lipid-lowering drugs on high-density lipoprotein subclasses in healthy men-a randomized trial.

2013

Context and Objective Investigating the effects of lipid-lowering drugs on HDL subclasses has shown ambiguous results. This study assessed the effects of ezetimibe, simvastatin, and their combination on HDL subclass distribution. Design and Participants A single-center randomized parallel 3-group open-label study was performed in 72 healthy men free of cardiovascular disease with a baseline LDL-cholesterol of 111±30 mg/dl (2.9±0.8 mmol/l) and a baseline HDL-cholesterol of 64±15 mg/dl (1.7±0.4 mmol/l). They were treated with ezetimibe (10 mg/day, n = 24), simvastatin (40 mg/day, n = 24) or their combination (n = 24) for 14 days. Blood was drawn before and after the treatment period. HDL subc…

MaleSimvastatinlcsh:MedicinePharmacologyBiochemistryLipoprotein MetabolismVascular MedicineSubclasslaw.inventionchemistry.chemical_compoundHigh-density lipoproteinRandomized controlled triallawMedicine and Health SciencesMedicinelcsh:ScienceHypolipidemic AgentsMultidisciplinaryHealthy VolunteersResearch DesignDrug Therapy Combinationlipids (amino acids peptides and proteins)Lipoproteins HDLResearch Articlemedicine.drugAdultmedicine.medical_specialtylipid-lowering drugs high-density lipoprotein healthy menDrug Research and DevelopmentClinical Research DesignLipoproteinsHypercholesterolemiaCardiologyAdipokineContext (language use)Research and Analysis MethodsCardiovascular PharmacologyAdipokinesEzetimibeInternal medicineHumansClinical TrialsPharmacologybusiness.industryCholesterollcsh:RBiology and Life SciencesProteinsnutritional and metabolic diseasesEzetimibeAtherosclerosisGlucoseEndocrinologychemistrySimvastatinAzetidineslcsh:QClinical MedicinebusinessBiomarkersPLoS ONE
researchProduct

Clinical efficacy and safety of Ezetimibe on major cardiovascular endpoints: systematic review and meta-analysis of randomized controlled trials.

2015

Background Randomized clinical trials (RCTs) about Ezetimibe's efficacy on patient-oriented outcomes have given discordant results. The aim of this study was to determine the net effect of Ezetimibe and of the widely marketed combination, Ezetimibe+simvastatin, on mortality and morbidity outcomes. Methods and Findings We searched for RCT on Ezetimibe using MEDLINE, CCTR, EMBASE, ClinicalTrials.gov databases up to December 2013, Merck and Novartis online registers, and personal communications. Two authors independently selected trials fulfilling these criteria: RCTs comparing Ezetimibe±statin or another lipid-lowering drug against placebo, or against the same lipid-lowering drug at the same …

MaleSimvastatinmedicine.medical_specialtylcsh:MedicineComorbidityPharmacologyPlacebolaw.inventionEzetimibeRandomized controlled triallawCardiovascular DiseaseCause of DeathInternal medicineAnticholesteremic AgentmedicineHumansAdverse effectlcsh:ScienceStrokeAgedRandomized Controlled Trials as TopicCause of deathMultidisciplinarybusiness.industryAnticholesteremic Agentslcsh:RMiddle AgedEzetimibemedicine.diseaseTreatment OutcomeCardiovascular DiseasesSimvastatinMeta-analysisDrug Therapy CombinationFemalelcsh:QbusinessResearch ArticleHumanmedicine.drugPLoS ONE
researchProduct

Economic evaluation of a guided and unguided internet-based CBT intervention for major depression: Results from a multicenter, three-armed randomized…

2017

Depression is one of the most common mental disorders and will become one of the leading causes of disability in the world. Internet-based CBT programs for depression have been classified as well established following the American Psychological Association criteria for empirically supported treatments. The aim of this study is to analyze the cost effectiveness at 12-month follow-up of the Internet-based CBT program Smiling is fun with (LITG) and without psychotherapist support (TSG) compared to usual care. The perspective used in our analysis is societal. A sample of 296 depressed patients (mean age of 43.04 years; 76% female; BDI-II mean score = 22.37) from primary care services in four Sp…

MaleSpanish PeopleEconomicsPsychological interventionSocial SciencesSeverity of Illness Indexlaw.invention:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]Learning and Memory0302 clinical medicineHispanoamericanosEthnicitiesPsychologyAnálisis de intención de tratarlcsh:Sciencemediana edadancianoDepressionAntidepressantsadulto:Health Care::Health Services Administration::Patient Care Management::Comprehensive Health Care::Primary Health Care [Medical Subject Headings]Humanosadulto joven:Health Care::Health Care Quality Access and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Epidemiologic Study Characteristics as Topic::Clinical Trials as Topic::Controlled Clinical Trials as Topic::Randomized Controlled Trials as Topic::Intention to Treat Analysis [Medical Subject Headings]Psicoterapia:Information Science::Information Science::Computing Methodologies::Computer Systems::Computer Communication Networks::Internet [Medical Subject Headings]medicine.medical_specialtyEvidence-based practiceGrupos control03 medical and health sciences:Health Care::Health Care Economics and Organizations::Economics::Costs and Cost Analysis::Cost-Benefit Analysis [Medical Subject Headings]Drug TherapySeverity of illnessHumans:Persons::Persons::Age Groups::Adult [Medical Subject Headings]psicoterapiaAgedPharmacologyDepressive DisorderDepressive Disorder MajorInternetPrimary Health CareMood Disorderslcsh:RBiology and Life SciencesSonrisa030227 psychiatryHealth CareAnálisis costo-beneficio:Check Tags::Female [Medical Subject Headings]Economic evaluationlcsh:QPopulation GroupingsNeuroscienceGerontologyFinancial ManagementCost effectivenessCost-Benefit Analysishumanosadolescentelcsh:MedicineTrastorno depresivoRandomized controlled triallawDepresiónMedicine and Health Sciences030212 general & internal medicineMultidisciplinaryAdultoPharmaceuticsresultado del tratamientoFemeninoDrugsCost-effectiveness analysisMiddle AgedTelemedicineTreatment OutcomeSociedades científicasFemale:Psychiatry and Psychology::Behavior and Behavior Mechanisms::Behavior::Communication::Nonverbal Communication::Facial Expression::Smiling [Medical Subject Headings]Estudios de seguimiento:Persons::Persons::Population Groups::Ethnic Groups::Hispanic Americans [Medical Subject Headings]telemedicinaResearch ArticleAdultAdolescent:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Methods::Research Design::Control Groups [Medical Subject Headings]:Psychiatry and Psychology::Behavioral Disciplines and Activities::Psychotherapy [Medical Subject Headings]Cost-Effectiveness AnalysisMEDLINEYoung Adulttrastorno depresivoAtención primaria de saludMental Health and PsychiatryIndirect CostsmedicineLearningíndice de gravedad de la enfermedadPrimary Care:Psychiatry and Psychology::Mental Disorders::Mood Disorders::Depressive Disorder [Medical Subject Headings]:Health Care::Health Care Economics and Organizations::Organizations::Societies::Societies Scientific [Medical Subject Headings]Cognitive Behavioral Therapybusiness.industryCognitive Psychology:Health Care::Health Care Quality Access and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Follow-Up Studies [Medical Subject Headings]Economic AnalysisPsychotherapyPeople and PlacesPhysical therapyCognitive Science:Psychiatry and Psychology::Behavior and Behavior Mechanisms::Behavior::Behavioral Symptoms::Depression [Medical Subject Headings]businessFinance
researchProduct

Estimating adjusted NNT measures in logistic regression analysis

2007

The number needed to treat (NNT) is a popular measure to describe the absolute effect of a new treatment compared with a standard treatment or placebo in clinical trials with binary outcome. For use of NNT measures in epidemiology to compare exposed and unexposed subjects, the terms 'number needed to be exposed' (NNE) and 'exposure impact number' (EIN) have been proposed. Additionally, in the framework of logistic regression a method was derived to perform point and interval estimation of NNT measures with adjustment for confounding by using the adjusted odds ratio (OR approach). In this paper, a new method is proposed which is based upon the average risk difference over the observed confou…

MaleStatistics and ProbabilityBiometryEpidemiologyInterval estimationCoverage probabilityCoronary DiseaseLogistic regressionCohort StudiesBiasRisk FactorsStatisticsConfidence IntervalsOdds RatioHumansMedicineClinical Trials as Topicbusiness.industrySmokingConfoundingConfounding Factors EpidemiologicOdds ratioConfidence intervalLogistic ModelsNumber needed to treatbusinessCohort studyStatistics in Medicine
researchProduct

RNA recognition by human TLR8 can lead to autoimmune inflammation

2013

High expression level of human TLR8 in mice results in spontaneous, multiorgan inflammation attributable in part to increased DC activation.

MaleT cellT-LymphocytesImmunologyArthritisInflammationMice TransgenicAutoimmunityTRL8AUTOIMMUNE INFLAMMATIONBiologymedicine.disease_causeArticleAutoimmunityProinflammatory cytokineMiceTRL8; AUTOIMMUNE INFLAMMATIONhemic and lymphatic diseasesmedicineImmunology and AllergyAnimalsHumansTransgenesChildRandomized Controlled Trials as TopicInflammationGene Expression ProfilingTLR7TLR8medicine.diseaseArthritis Experimentaldigestive system diseasesArthritis JuvenileMice Inbred C57BLmedicine.anatomical_structureToll-Like Receptor 7Toll-Like Receptor 8ImmunologyRNAFemaleCollagenSignal transductionmedicine.symptomSignal TransductionThe Journal of Experimental Medicine
researchProduct

Cost effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C.

2013

Background & Aims Randomised controlled trials (RCTs) show that triple therapy (TT) with peginterferon alfa, ribavirin, and boceprevir (BOC) or telaprevir (TVR) is more effective than peginterferon-ribavirin dual therapy (DT) in the treatment of genotype 1 (G1) chronic hepatitis C (CHC) patients with previous relapse (RR), partial response (PAR), and null-response (NR). We assess the cost-effectiveness of TT compared to no therapy in the treatment of patients previously treated with G1 CHC. Methods The available published literature provided the data source. The target population was made up of previously treated Caucasian patients with G1 CHC and these were evaluated over a lifetime horizo…

MaleTVRCost effectivenessCost-Benefit AnalysisPIPeginterferon-alfaBOCHepacivirusBOC Boceprevir CHC Cost-effectiveness DT G1 ICER NR PAR PI PegIFN RBV RR TVR Telaprevir boceprevir chronic hepatitis C dual therapy genotype 1 incremental cost-effectiveness ratio non-response partial response pegylated interferon protease inhibitors relapse ribavirin telaprevirTelaprevirTelaprevirchemistry.chemical_compoundPegylated interferonnon-responseboceprevirincremental cost-effectiveness ratioRBVTreatment FailureDThealth care economics and organizationsRandomized Controlled Trials as Topicrelapsecost effectivenessICERMiddle AgedMarkov ChainsModels EconomicItalyQuality-Adjusted Life YearsSettore SECS-P/02 - politica economicaSettore SECS-S/01 - StatisticaIncremental cost-effectiveness ratioOligopeptidesmedicine.drugmedicine.medical_specialtyGenotypeProlineribavirinSettore MED/12 - GASTROENTEROLOGIAprotease inhibitorsNRRRAntiviral AgentsInternal medicineBoceprevirG1medicineHumanschronic hepatitis Cpegylated interferongenotype 1Hepatologybusiness.industryRibavirindual therapyHepatitis C ChronicQuality-adjusted life yearSurgeryCHCPegIFNchemistryCost-effectivenesspartial responsebusinessPAR
researchProduct